Patented IRPL® Technology Now Available in Canada
Friday, May 1 2020 | 15 h 35 min | News
I-MED Pharma announces Health Canada approval for the E>Eye Laser, which is now available to Canadian eye care professionals. With exclusive Canadian distribution rights, I-MED Pharma brings this device to the Canadian marketplace.
E>Eye is the first and only CE certified medical device in the world using patented IRPL® technology developed specifically for the treatment of dry eye disease caused by meibomian gland dysfunction (MGD), the leading cause of evaporative dry eye.
This new type of polychromatic pulsed light produces perfectly calibrated and homogeneously sequenced “cold light” pulses which safely stimulate the meibomian glands to resume secretions, restoring the lacrymal film and improving symptoms associated with ocular dryness.
Daniel Hofmann, President of I-MED Pharma stated, “The E>Eye is a revolutionary device that offers patients an affordable, long-lasting solution for dry eye management. It is radically different from other existing treatment options for dry eye disease and it has many advantages over traditional IPL devices currently on the market.”
Click HERE for the full press release.
